Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label infliximab monotherapy for refractory endogenous uveitis or retinal vasculitis
NL-OMON20017Suspended
- Sponsor
- AMC Medical Research
- Start
- Nov 2001
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in uveitis and retinal vasculitis (RV), sponsored by AMC Medical Research. Primary endpoint: Successful tapering of concomitant immunosuppressants without treatment failure. Started Nov 2001; status: suspended.
02
Drugs
infliximab
03
Conditions
uveitisretinal vasculitis (RV)
Beyond the preview
Go deeper on NL-OMON20017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20017.